Orphan drug regulations in Turkey

Journal of Pharmaceutical Health Services Research

Volumn 4, Issue 3, 2013, Pages 151-153

  Kiliç, Pelin ^a   Koçkaya, Güvenç ^b   Yemşen, Ömer ^a   Tan, Celil ^c   Öztunca, Fikriye Handan ^a   Aksungur, Pelin ^a   Kerman, Saim ^a  

^a Turkish Medicines and Medical Devices Agency (TITCK)   (Turkey)

^b Health Economics and Policy Association (HEPA)   (Turkey)

^c Alfa Farma Pharmaceuticals   (Turkey)

Author keywords

Market access; Orphan drugs; Prevalence; Regulation; Turkey

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; DRUG UTILIZATION; EUROPE; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HUMAN; PREVALENCE; PRIORITY JOURNAL; RARE DISEASE; REIMBURSEMENT; TURKEY (REPUBLIC); UNITED STATES;

EID: 84881653320     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/jphs.12018     Document Type: Article

References (9)

1. Committee for Orphan Medicinal Products and the European Medicines, Westermark K etal. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 2011; 10: 341-349.
2. Salvatore M etal. The role of microRNAs in the biology of rare diseases. Int J Mol Sci 2011; 12: 6733-6742.
3. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011; 6: 42.
4. Turkish Medicines and Medical Devices Agency (TİTCK). Communiqué regarding Pricing of Pharmaceuticals for Human Use. Ankara: TİTCK, 2013 [in Turkish]. http://www.titck.gov.tr/Default.aspx?sayfa=regulations&lang=en&thelawtype=14&thelawId=307 (accessed 11 January 2013).
5. Miyamato BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis 2011; 6: 49.
6. Wellman-Labadie O, Zhou Y. The US orphan drug act: rare disease research stimulator or commercial opportunity? Health Policy 2010; 95: 216-228.
7. Liu BC etal. A cross-national comparative study of orphan drug policies in the United States, the European Union and Japan: towards a made-in-China orphan drug policy. J Public Health Policy 2010; 31: 407-420.
8. Tauruscio D etal. Rare diseases and orphan drugs. Ann Ist Super Sanita 2011; 47: 83-93.
9. Turkish Medicines and Medical Devices Agency (TİTCK). About Pricing of Pharmaceuticals for Human Use: Amendment of the Communiqué. Ankara: TİTCK, 2013 [in Turkish]. http://www.titck.gov.tr/Default.aspx?sayfa=iegm_mevzuat&lang=tr-TR&thelawtype=5&thelawId=427 (accessed 11 January 2013).